A detailed history of American International Group, Inc. transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, American International Group, Inc. holds 19,236 shares of ORIC stock, worth $144,654. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,236
Previous 19,401 0.85%
Holding current value
$144,654
Previous $178,000 48.31%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$8.04 - $16.03 $1,326 - $2,644
-165 Reduced 0.85%
19,236 $264,000
Q4 2023

Feb 13, 2024

SELL
$5.41 - $9.43 $427 - $744
-79 Reduced 0.41%
19,401 $178,000
Q3 2023

Nov 13, 2023

BUY
$6.05 - $9.28 $4,192 - $6,431
693 Added 3.69%
19,480 $117,000
Q2 2023

Aug 04, 2023

BUY
$4.95 - $8.4 $92,995 - $157,810
18,787 New
18,787 $145,000
Q2 2022

Aug 12, 2022

SELL
$2.7 - $7.07 $42,381 - $110,977
-15,697 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$4.54 - $16.1 $5,016 - $17,790
-1,105 Reduced 6.58%
15,697 $84,000
Q4 2021

Feb 11, 2022

SELL
$12.01 - $20.3 $6,041 - $10,210
-503 Reduced 2.91%
16,802 $247,000
Q3 2021

Nov 12, 2021

BUY
$15.9 - $25.22 $12,258 - $19,444
771 Added 4.66%
17,305 $362,000
Q2 2021

Aug 13, 2021

BUY
$17.37 - $25.34 $57,789 - $84,306
3,327 Added 25.19%
16,534 $292,000
Q1 2021

May 07, 2021

BUY
$23.67 - $36.85 $7,314 - $11,386
309 Added 2.4%
13,207 $324,000
Q4 2020

Feb 12, 2021

BUY
$20.32 - $39.8 $156,281 - $306,101
7,691 Added 147.71%
12,898 $437,000
Q3 2020

Nov 04, 2020

SELL
$19.5 - $31.26 $2,301 - $3,688
-118 Reduced 2.22%
5,207 $130,000
Q2 2020

Aug 12, 2020

BUY
$25.68 - $38.12 $136,746 - $202,989
5,325 New
5,325 $180,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $298M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.